HFA Icon

Amylin Attacked By Carl Icahn Over Buyout Secrecy

HFA Padded
HFA Staff
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

Amylin Attacked By Carl Icahn Over Buyout Secrecy

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) was under attack today from Carl Icahn over the board of that company's refusal to comment on rumors of a rejected takeover offer. Icahn, who holds an almost 9% stake in the company, was irate after an offer of $22 per share may or may not have been rejected by the company and the company would not confirm or deny the rumors. The $22 offer apparently came from Bristol Myers Squibb and shareholders were not informed of the offer by the board in any way. Information about the...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

The post above is drafted by the collaboration of the Hedge Fund Alpha Team.